AstraZeneca stops lung cancer trial early, after star drug Tagrisso induces 'overwhelming' efficacy
A pivotal lung cancer trial testing Tagrisso, AstraZeneca’s bestselling oncology therapy, has been halted due to “overwhelming” efficacy.
The 682 patient-trial, ADAURA, was evaluating the drug against a placebo in non-small cell lung cancer patients with EGFR mutations who had undergone tumor resection and optional, standard postoperative adjuvant chemotherapy. In the Tagrisso arm, patients were to be treated with the 80 mg drug once-daily for three years, or until the cancer returned — and the data readout was scheduled for 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.